Form 4: Nantahala Capital Management Sells Evoke Pharma Shares

Nantahala Capital Management, along with related individuals, reported the sale of 41 shares of Evoke Pharma Inc. at a price of $4.3871 per share.

Summary

• Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, filed a Form 4 indicating a change in beneficial ownership of Evoke Pharma Inc. securities.
• The transaction involved the sale of 41 shares of common stock on January 28, 2025, at a price of $4.3871 per share.
• Following the transaction, Nantahala Capital Management indirectly beneficially owns 148,153 shares of Evoke Pharma Inc.
• Nantahala Capital Management acts as an investment advisor to private funds and managed accounts that hold the Evoke Pharma securities.
• Wilmot B. Harkey and Daniel Mack may be deemed beneficial owners of the securities held by Nantahala Capital Management.

Sentiment

Score: 5

Explanation: The document is neutral, reporting a routine transaction. There is no indication of positive or negative sentiment towards the company.

Negatives

• Nantahala Capital Management reduced its holdings in Evoke Pharma Inc. by selling 41 shares.

Risks

• The sale of shares by a significant shareholder like Nantahala Capital Management could potentially signal a change in sentiment towards the company.
• Further sales by Nantahala Capital Management could put downward pressure on the stock price.

Management Comments

• Nantahala Capital Management, Mr. Harkey, and Mr. Mack disclaim beneficial ownership of the Issuer's securities except to the extent of their respective pecuniary interests therein.

Industry Context

Form 4 filings are a standard part of regulatory compliance for significant shareholders and insiders, providing transparency into their trading activities. This filing indicates a minor reduction in holdings by a major shareholder.

Comparison to Industry Standards

• Form 4 filings are common across all publicly traded companies in the US.
• The sale of 41 shares is a very small transaction compared to the total holdings of 148,153 shares, and is unlikely to be significant compared to the trading volume of similar companies.
• Other companies with similar filings include those with significant institutional ownership, such as biotech firms with venture capital backing.

Stakeholder Impact

• The sale of shares may have a minor negative impact on shareholder sentiment, but the small size of the transaction is unlikely to cause significant concern.

Key Dates

Keywords

Evoke Pharma, Nantahala Capital Management, Beneficial Ownership, Form 4, Share Sale, Stock Transaction